
Stefanie S Jeffrey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9325576/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interpretable Classification of Bacterial Raman Spectra With Knockoff Wavelets. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 740-748.	6.3	5
2	Liquid biopsy enters the clinic — implementation issues and future challenges. Nature Reviews Clinical Oncology, 2021, 18, 297-312.	27.6	609
3	Targeting the tetraspanin CD81 reduces cancer invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	29
4	Encapsulated Cell Dynamics in Droplet Microfluidic Devices with Sheath Flow. Micromachines, 2021, 12, 839.	2.9	1
5	Cell-free circulating tumor DNA profiling in cancer management. Trends in Molecular Medicine, 2021, 27, 1014-1015.	6.7	17
6	Gold Nanobipyramids as Second Near Infrared Optical Coherence Tomography Contrast Agents for <i>in Vivo</i> Multiplexing Studies. Nano Letters, 2020, 20, 101-108.	9.1	28
7	Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients. Frontiers in Oncology, 2020, 10, 572895.	2.8	35
8	Plasmonic and Electrostatic Interactions Enable Uniformly Enhanced Liquid Bacterial Surface-Enhanced Raman Scattering (SERS). Nano Letters, 2020, 20, 7655-7661.	9.1	56
9	Guided-Mode-Resonant Dielectric Metasurfaces for Colorimetric Imaging of Material Anisotropy in Fibrous Biological Tissue. ACS Photonics, 2020, 7, 3216-3227.	6.6	13
10	Electropermanent magnet-driven droplet size modulation for two-phase ferromicrofluidics. Microfluidics and Nanofluidics, 2020, 24, 1.	2.2	5
11	Deciphering cancer clues from blood. Science, 2020, 367, 1424-1425.	12.6	20
12	Toward rapid infectious disease diagnosis with advances in surface-enhanced Raman spectroscopy. Journal of Chemical Physics, 2020, 152, 240902.	3.0	46
13	Tumor shedding and metastatic progression after tumor excision in patient-derived orthotopic xenograft models of triple-negative breast cancer. Clinical and Experimental Metastasis, 2020, 37, 413-424.	3.3	10
14	Extracellular Vesicle–Mediated <i>In Vitro</i> Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity. Molecular Cancer Therapeutics, 2020, 19, 858-867.	4.1	33
15	Advances in the Characterization of Circulating Tumor Cells in Metastatic Breast Cancer: Single Cell Analyses and Interactions, and Patient-Derived Models for Drug Testing. Advances in Experimental Medicine and Biology, 2020, 1220, 61-80.	1.6	10
16	Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor <scp>DNA</scp> . Molecular Oncology, 2019, 13, 1623-1650.	4.6	64
17	Rapid identification of pathogenic bacteria using Raman spectroscopy and deep learning. Nature Communications, 2019, 10, 4927.	12.8	416
18	Neural network-based model of photoresist reflow. Journal of Vacuum Science and Technology B:Nanotechnology and Microelectronics, 2019, 37, .	1.2	1

#	Article	IF	CITATIONS
19	Anomalous hysteresis and current fluctuations in cyclic voltammograms at microelectrodes due to Ag leaching from Ag/AgCl reference electrodes. Electrochemistry Communications, 2019, 105, 106499.	4.7	6
20	Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer. Breast Cancer Research, 2019, 21, 98.	5.0	31
21	Liquid biopsy: a perspective for probing blood for cancer. Lab on A Chip, 2019, 19, 548-549.	6.0	25
22	Scalable methods for ultra-smooth platinum in nanoscale devices. Micro and Nano Engineering, 2019, 3, 50-58.	2.9	5
23	ALD HfO ₂ Films for Defining Microelectrodes for Electrochemical Sensing and Other Applications. ACS Applied Materials & amp; Interfaces, 2019, 11, 26082-26092.	8.0	6
24	Real-Time Detection of Circulating Tumor Cells in Living Animals Using Functionalized Large Gold Nanorods. Nano Letters, 2019, 19, 2334-2342.	9.1	17
25	Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation. Molecular Cancer Therapeutics, 2018, 17, 1133-1142.	4.1	107
26	Fast and Label-Free Isolation of Circulating Tumor Cells from Blood: From a Research Microfluidic Platform to an Automated Fluidic Instrument, VTX-1 Liquid Biopsy System. SLAS Technology, 2018, 23, 16-29.	1.9	40
27	Future of Liquid Biopsies With Growing Technological and Bioinformatics Studies: Opportunities and Challenges in Discovering Tumor Heterogeneity With Single-Cell Level Analysis. Cancer Journal (Sudbury, Mass), 2018, 24, 104-108.	2.0	34
28	Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology. Npj Precision Oncology, 2017, 1, 15.	5.4	72
29	Profiling protein expression in circulating tumour cells using microfluidic western blotting. Nature Communications, 2017, 8, 14622.	12.8	201
30	Workflow optimization of whole genome amplification and targeted panel sequencing for CTC mutation detection. Npj Genomic Medicine, 2017, 2, 34.	3.8	42
31	5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. Cell Research, 2017, 27, 1231-1242.	12.0	200
32	T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10409-E10417.	7.1	53
33	Enumeration and targeted analysis of <i>KRAS</i> , <i>BRAF</i> and <i>PIK3CA</i> mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. Oncotarget, 2016, 7, 85349-85364.	1.8	79
34	Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology. Oncotarget, 2016, 7, 12748-12760.	1.8	151
35	Electropermanent magnet actuation for droplet ferromicrofluidics. Technology, 2016, 04, 110-119.	1.4	14
36	Label-free enumeration, collection and downstream cytological and cytogenetic analysis of circulating tumor cells. Scientific Reports, 2016, 6, 35474.	3.3	46

#	Article	IF	CITATIONS
37	Circulating tumor cell technologies. Molecular Oncology, 2016, 10, 374-394.	4.6	432
38	Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy. Oncotarget, 2016, 7, 54811-54824.	1.8	8
39	High efficiency vortex trapping of circulating tumor cells. Biomicrofluidics, 2015, 9, 064116.	2.4	60
40	Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget, 2015, 6, 2549-2561.	1.8	96
41	HIGD1A Regulates Oxygen Consumption, ROS Production, and AMPK Activity during Glucose Deprivation to Modulate Cell Survival and Tumor Growth. Cell Reports, 2015, 10, 891-899.	6.4	79
42	Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. Clinical Cancer Research, 2015, 21, 4786-4800.	7.0	310
43	Impact of Navigation on Knowledge and Attitudes About Clinical Trials Among Chinese Patients Undergoing Treatment for Breast and Gynecologic Cancers. Journal of Immigrant and Minority Health, 2015, 17, 976-979.	1.6	11
44	High-Throughput Time-Resolved FRET Reveals Akt/PKB Activation as a Poor Prognostic Marker in Breast Cancer. Cancer Research, 2014, 74, 4983-4995.	0.9	24
45	Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Research, 2014, 16, R36.	5.0	63
46	Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. Lab on A Chip, 2014, 14, 78-88.	6.0	149
47	Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer, 2014, 14, 456.	2.6	93
48	Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. Expert Review of Molecular Diagnostics, 2013, 13, 581-599.	3.1	55
49	Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?. Genome Medicine, 2013, 5, 70.	8.2	84
50	Nuclear Localization of the Mitochondrial Factor HIGD1A during Metabolic Stress. PLoS ONE, 2013, 8, e62758.	2.5	32
51	Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLoS ONE, 2012, 7, e33788.	2.5	475
52	Distinctive Responsiveness to Stromal Signaling Accompanies Histologic Grade Programming of Cancer Cells. PLoS ONE, 2011, 6, e20016.	2.5	10
53	A pharmacogenomic method for individualized prediction of drug sensitivity. Molecular Systems Biology, 2011, 7, 513.	7.2	43
54	Adipose levels of polybrominated diphenyl ethers and risk of breast cancer. Breast Cancer Research and Treatment, 2011, 129, 505-511.	2.5	42

#	Article	IF	CITATIONS
55	Characterization of molecular subtypes of Korean breast cancer: An ethnically and clinically distinct population. International Journal of Oncology, 2010, 37, 51-9.	3.3	0
56	Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3970-3975.	7.1	448
57	DNA copy number alterations and expression of relevant genes in tripleâ€negative breast cancer. Genes Chromosomes and Cancer, 2008, 47, 490-499.	2.8	91
58	Cancer biomarker profiling with microRNAs. Nature Biotechnology, 2008, 26, 400-401.	17.5	101
59	New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer, 2008, 8, 66.	2.6	216
60	<i>CAMK1D</i> amplification implicated in epithelial–mesenchymal transition in basalâ€like breast cancer. Molecular Oncology, 2008, 2, 327-339.	4.6	55
61	Estrogen Receptor–Negative Invasive Breast Cancer: Imaging Features of Tumors with and without Human Epidermal Growth Factor Receptor Type 2 Overexpression. Radiology, 2008, 246, 367-375.	7.3	135
62	Disease-specific genomic analysis: identifying the signature of pathologic biology. Bioinformatics, 2007, 23, 957-965.	4.1	48
63	TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Research, 2007, 9, R30.	5.0	244
64	Transcriptomic signatures in breast cancer. Molecular BioSystems, 2007, 3, 466.	2.9	10
65	RNA extraction from ten year old formalin-fixed paraffin-embedded breast cancer samples: a comparison of column purification and magnetic bead-based technologies. BMC Molecular Biology, 2007, 8, 118.	3.0	113
66	Discovery and validation of breast cancer subtypes. BMC Genomics, 2007, 8, 101.	2.8	2
67	Radiation-induced effects on gene expression: An in vivo study on breast cancer. Radiotherapy and Oncology, 2006, 80, 230-235.	0.6	22
68	Lysyl oxidase is essential for hypoxia-induced metastasis. Nature, 2006, 440, 1222-1226.	27.8	1,231
69	Discovery and validation of breast cancer subtypes. BMC Genomics, 2006, 7, 231.	2.8	102
70	Cell Trapping in Activated Micropores for Functional Analysis. , 2006, 2006, 1838-41.		4
71	Cell Trapping in Activated Micropores for Functional Analysis. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0
72	Genomics-Based Prognosis and Therapeutic Prediction in Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 291-300.	4.9	54

#	Article	IF	CITATIONS
73	A streamlined platform for high-content functional proteomics of primary human specimens. Nature Methods, 2005, 2, 691-697.	19.0	225
74	Rates of reexcision for breast cancer after magnetic resonance imaging-guided bracket wire localization. Journal of the American College of Surgeons, 2005, 200, 527-537.	0.5	45
75	Adipose levels of dioxins and risk of breast cancer. Cancer Causes and Control, 2005, 16, 525-535.	1.8	19
76	MRI Features of Mucosa-Associated Lymphoid Tissue Lymphoma in the Breast. American Journal of Roentgenology, 2005, 185, 199-202.	2.2	22
77	The Evolution of Accelerated, Partial Breast Irradiation as a Potential Treatment Option for Women with Newly Diagnosed Breast Cancer Considering Breast Conservation. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 673-705.	1.0	12
78	Different Gene Expression Patterns in Invasive Lobular and Ductal Carcinomas of the Breast. Molecular Biology of the Cell, 2004, 15, 2523-2536.	2.1	540
79	Magnetic Resonance Imaging of Suspicious Breast Masses Seen on One Mammographic View. Breast Journal, 2004, 10, 416-422.	1.0	11
80	A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics, 2004, 5, 47.	2.8	51
81	Distribution of persistent, lipid-soluble chemicals in breast and abdominal adipose tissues: lessons learned from a breast cancer study. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 416-24.	2.5	18
82	The diagnosis and management of pre-invasive breast disease: Promise of new technologies in understanding pre-invasive breast lesions. Breast Cancer Research, 2003, 5, 320-8.	5.0	22
83	Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12963-12968.	7.1	1,098
84	MR Imaging Features of Infiltrating Lobular Carcinoma of the Breast. American Journal of Roentgenology, 2002, 178, 1227-1232.	2.2	86
85	Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis. BMC Genomics, 2002, 3, 31.	2.8	124
86	Expression Array Technology in the Diagnosis and Treatment of Breast Cancer. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2002, 2, 101-109.	3.4	26
87	Locally Advanced Breast Cancer: Is Surgery Necessary?. Breast Journal, 2001, 7, 131-137.	1.0	27
88	Freehand iMRI-guided large-gauge core needle biopsy: A new minimally invasive technique for diagnosis of enhancing breast lesions. Journal of Magnetic Resonance Imaging, 2001, 13, 896-902.	3.4	44
89	Breast Cancer: Variables Affecting Sentinel Lymph Node Visualization at Preoperative Lymphoscintigraphy. Radiology, 2001, 220, 47-53.	7.3	73
90	Management of Breast Cancer After Hodgkin's Disease. Journal of Clinical Oncology, 2000, 18, 765-765.	1.6	138

#	Article	IF	CITATIONS
91	Characterization of breast lesion morphology with delayed 3DSSMT: An adjunct to dynamic breast MRI. Journal of Magnetic Resonance Imaging, 2000, 11, 87-96.	3.4	48
92	Systematic variation in gene expression patterns in human cancer cell lines. Nature Genetics, 2000, 24, 227-235.	21.4	1,946
93	Molecular portraits of human breast tumours. Nature, 2000, 406, 747-752.	27.8	13,397
94	Controversies in Sentinel Lymph Node Biopsy for Breast Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2000, 15, 223-233.	1.0	16
95	Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nature Genetics, 1999, 23, 41-46.	21.4	928
96	2035 Management of breast cancer following Hodgkin's disease. International Journal of Radiation Oncology Biology Physics, 1997, 39, 258.	0.8	1
97	The importance of the lumpectomy surgical margin status in long term results of breast conservation. Cancer, 1995, 76, 259-267.	4.1	390